Dermatology Times, December 2023 (Vol. 44 No. 12)

Learn more about the in-depth topics covered in the December 2023 print issue of Dermatology Times.

Dr Derm has recently been sued by a patient for simply asking the question “Do you own a gun?” He seeks legal advice.

Aesthetic procedures for patients with skin of color necessitate a nuanced approach that prioritizes patient safety and optimal outcomes.

Check out these 5 factors that can significantly impact a dermatologist’s financial plan and should therefore incorporate flexibility and resiliency to structure the plan for long-term success.

Roundtable participants shared 10 different considerations to make for a patient, like this 23-year old woman, with a new environment and lifestyle.

The Society for Immunotherapy of Cancer recently published insights into the management of patients with preexisting autoimmune disease, solid organ transplant recipients, elderly individuals, those living with HIV, pregnant patients, and those with rare noncutaneous subtypes of melanoma.

Review a rundown of our top articles and resources for patients inspired by National Eczema Awareness Month.

A recent study presents a unique case of sudden-onset vitiligo following the COVID-19 vaccination, along with a systematic review of existing literature to shed light on the potential link between vaccination and vitiligo development.

Here is a recap of the drugs and treatments approved to keep in mind for the new year.

The emergence of JAK inhibitors has shown tremendous promise as a novel therapeutic approach.

Cognizance and certain clues may help dermatologists in recognizing antifungal-resistant dermatophyte infections.

Staying on top of products and ingredients patients are asking about is critical, especially this holiday season as they are considering gifts for loved ones.

Researchers have explored whether the adverse effects of tazarotene are exacerbated during the colder winter months and whether there is variation in treatment efficacy and tolerability between cold vs warm seasons.

From the December cover feature: Christopher Bunick, MD, PhD; Aaron Drucker, MD, ScM; and Mona Shahriari, MD, share their thoughts on AAD’s updated atopic dermatitis guidelines.

The holidays are a wonderful time to catch up with family members on where the journey of life has taken us during the past year, but they are also a time to share microbiome organisms with others who are genetically similar to us.

As 2023 ends and 2024 approaches, we are thankful for a year dedicated to new therapeutics for patients in need, and we look forward to a new year of continued innovations.

Members of Dermatology Times’ Editorial Advisory Board share their perspectives on the most meaningful innovations of the year this Thanksgiving Day.

This week’s collection of the latest dermatologic studies covers the relationship between melanoma pigmentation and inflammatory cytokines, the negative use of topical nystatin for tinea infections, the association between psoriasis and schizophrenia, and the association between pediatric atopic dermatitis and cardiovascular risk factors.

This week’s collection of the latest dermatologic studies covers atypical molluscum contagiosum lesions with a CD30-positive T-cell lymphoid infiltrate, comorbidities in pediatric psoriasis, tralokinumab for adolescents with severe AD, and intralesional bleomycin combined with lidocaine for recalcitrant keloid scars.

Poster presented at American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting yields positive results for adults and children 2 years age and up.

A new study presented at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights the need for mental health support in patients with atopic dermatitis.

Rebecca Vasquez, MD, presented a session on common, overlapping, and complex pigmented dermatoses.

More than 80% of patients did not experience an increase in number of draining tunnels associated with HS by week 52.

The most common conditions or concerns patients reported having that may influence their selection of a JAK inhibitor included an increased risk of MACE and an age above 65 years.

Francesca Tenconi, president and CEO of Children’s Skin Disease Foundation and Camp Wonder, presented at Fall Clinical 2023 about the challenges of chronic skin conditions in children.